Pluristem Initiates Two Pivotal Phase III Studies in Israel

Author's Avatar
Aug 08, 2018
Article's Main Image

Numerous Clinical Sites in Israel to join sites in the U.S. and Europe for Pivotal Phase III Studies of PLX-PAD Cell Therapy in the Treatment of Critical Limb Ischemia and Muscle Injury Following Hip Fracture